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Abstract
Objective: We studied decision-making regarding inhaled nitric oxide (iNO) in preterm infants 
with Pulmonary Hypertension (PH).
Study Design: We asked members of the AAP-Society of Neonatal-Perinatal Medicine and 
Division-Chiefs to select from three management options-initiate iNO, engage parents in shared-
decision-making or not consider iNO in an extremely preterm with PH followed by rating of 
factors influencing their decision.
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Results: 304 respondents (9%) completed the survey; 36.5% chose to initiate iNO, 42% to 
engage parents, and 21.5% did not consider iNO. Provider’s prior experience, safety, and patient-
centered care were rated higher by those who initiated or offered iNO; lack of effectiveness and 
cost-considerations by participants who did not chose iNO.
Conclusions: Most neonatologists offer or initiate iNO therapy based on their individual 
experience. The minority who chose not to consider iNO placed higher value on lack of 
effectiveness and cost. These results demonstrate a tension between evidence and 
pathophysiology-based-therapy/personal experience.
Keywords
hypoxic respiratory failure; prematurity; cost-effectiveness; evidence based medicine; medical 
decision making; clinical practice guidelines
Pulmonary hypertension (PH) affects 8.1% of extremely preterm neonates and is associated 
with high mortality (20.5%) and morbidity.1 Treatment options are limited and include 
inhaled nitric oxide (iNO) and sildenafil. These therapies are not approved in preterm infants 
by the US Food and Drug Administration. Although iNO is a proven effective2 treatment 
strategy in term and near-term infants with persistent PH of the newborn, its efficacy in 
preterm neonates is less certain.3 An individual patient level meta-analysis of premature 
infants enrolled in randomized controlled trials using iNO found no significant effect on 
death or chronic lung disease 4; a Cochrane review found no improvement in outcomes with 
iNO with a potential for harm in the form of severe intraventricular hemorrhage.5 Selective 
use of iNO among preterm infants with hypoxemic respiratory failure (HRF) associated with 
oligohydramnios and pulmonary hypoplasia 678 and/or echocardiographic evidence of PH 
9, 10
 is considered by several experts in the field and is an option according to The National 
Institute of Health (NIH) 11 and American Heart Association/American Thoracic Society 
(AHA/ATS) guideline12 recommendations. However, the American Academy of Pediatrics’ 
(AAP) Committee of the Fetus and Newborn 3 clinical report makes no such exception 
based on randomized controlled trials evaluating preterm infants with respiratory failure. It 
states that neither rescue nor routine use of iNO improves survival in preterm infants with 
respiratory failure. This decision was based on studies, which did not have treatment of 
specific PH as their primary objective. The NIH consensus statement (2011),11 AAP (2014), 
3
 AHA/ATS (2015),12 and Pediatric Pulmonary Hypertension Society guidelines (2016) 14 
and the Cochrane review results are summarized in Table 1. Selective use of iNO in infants 
with pulmonary hypoplasia and PH, as documented by echocardiography, (this is 
recommended by the Pediatric Pulmonary Hypertension Society guidelines14) has not been 
evaluated in a large randomized, controlled trial. Therapy with iNO is expensive (average 
approximately $125 15 to $147 USD per hour of use irrespective of dose), cost varies based 
on contractual agreements.
Despite limited evidence for benefit and the potential for harm, the use of iNO in preterm 
infants with PH and/or HRF is common.16 The use of iNO among preterm infants has not 
decreased after publication of the AAP clinical practice guidelines (CPGs). Finer and Evans 
opine that this persistent use of iNO in preterm infants is not due to ignorance of the 
evidence; rather an instinct to attempt to normalize physiology of PH when faced with a 
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hypoxemic infant.17 There is a paucity of randomized controlled trials evaluating the effect 
of iNO on mortality in extremely preterm infants with pretreatment echocardiographic 
evidence of PH. 1813 Understanding the factors that influence use of iNO in preterm infants 
is essential to designing and implementing strategies that will increase evidence-based high-
value care.
Therefore, using a clinical vignette of an extremely premature infant with PH and HRF 
associated with prolonged rupture of membranes, we asked neonatologists to specify the 
importance of factors in deciding whether to use iNO. The purpose of this study was to 
address determinants of neonatologists’ clinical decisions in the setting of limited evidence 
of effectiveness, high resource use, and conflicting CPG recommendations. We also 
evaluated reasons for failure to implement the evidence and value based AAP clinical report.
Materials and Methods
The study was approved by the Institutional review board at the University at Buffalo, 
Buffalo New York, USA and the Hamilton Integrated Research Ethics Board at McMaster 
University, Hamilton, Ontario, Canada. The details of the study protocol for conducting 
surveys using clinical vignettes and analysis of data to determine factors influencing 
clinical-decision making were published in the European Journal of Person Centered 
Healthcare 19.
To capture the elements of quality of healthcare, many organizations 20 and researchers21 
have adopted the Institute of Medicine (IOM)’s framework for quality of care 22. This 
framework organizes the determinants of quality into six domains: safety, effectiveness 
(evidence-based), patient-centered-care, timely, efficient (cost considerations) and equitable. 
The domains of timeliness and equity were not applicable to the clinical vignette presented 
in this study, the remaining four domains and three additional factors that may influence 
clinical decisions including local hospital practice23, 24, medicolegal concerns25 and 
provider’s prior experience26 were included in this study.
Development of the survey:
Experienced clinicians and researchers in neonatology developed the case description. The 
clinical sensibility of the case scenario was confirmed during pilot testing with a group of 12 
neonatologists and the survey was modified based on their feedback. A second round of pilot 
testing was performed with a separate group of five neonatologists and confirmed the 
clinical sensibility of the case scenario, response options and the factors included for rating.
Case description
Figure 1 presents the final case description. This was designed such that the infant would 
meet criteria for initiation of iNO therapy based on the PH physiology-based-approach as 
per the ATS/AHA guidelines 12, include an option for possible shared decision-making 
(SDM) according to NIH guidelines but would not meet the AAP clinical report guidelines 3 
for treatment. Respondents chose from three responses regarding the use of iNO: Initiate 
iNO; explicitly discuss the potential benefits, side effects and costs with parents before 
making a decision to offer iNO (SDM); or not to consider iNO. After choosing one of the 
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three options, participants rated the importance of the seven factors in their decision on a 7-
point Likert scale from ‘unimportant’ to ‘critically important’. Participants then reviewed 
current CPG recommendations, were asked to reflect further on their decision, and asked 
whether the additional information changed their management plan (yes or no response). 
Respondents had the opportunity to provide a free text response commenting on their 
reasoning. Finally, respondents reviewed a scenario of payment refusal by the third-party 
payer resulting in financial burden to parents followed by a question asking if this additional 
information would change their clinical decision (yes or no response) and an opportunity to 
provide comments.
Survey administration:
The survey was anonymous, administered via email through the Section on Neonatal 
Perinatal Medicine (SoNPM) of the AAP (approximately 3302 email addresses at the time 
of this survey) 27 on September 29, 2017 and to Neonatology Division Chiefs email list (113 
members on the day of the survey) on November 10, 2017 using a URL (uniform resource 
locator) link. The mailing list of SoNPM includes 100 neonatal nurse practitioners, 350 
fellows and 200 Pediatricians. Many members of the Neonatal Division chiefs mailing list 
are also members of the SoNPM. The survey was conducted and data collected using the 
SurveyMonkey® platform (SurveyMonkey®, San Mateo CA).
Statistical Analysis:
Results were analyzed in IBM SPSS statistics for windows (IBM, Armonk NY). All data 
were explored using descriptive statistics. To determine if the average ratings of the seven 
factors differed relative to the management option selected, we conducted a repeated 
measures analysis of variance (ANOVA). The ratings of the seven factors were included as 
within subject factors and the choice of management option as a between subjects factor. 
Further exploration of possible interactions was conducted using a multinomial logistic 
regression. The dependent variable had three management options as the outcomes (initiate 
iNO, SDM or not consider iNO). The independent variables were the seven factors. The 
reference category for this analysis was the option to not offer iNO therapy. The association 
of demographic characteristics with selection of management plan was examined using chi-
squared tests. Free text responses were analyzed using basic content analytic strategies.28, 29
Results
Of 336 participants who started the survey, 90% completed it. Majority of respondents 
(61%) were from an academic setting, 24% from private practice, 12% were hospital 
employees and 3% had other affiliations. Almost half (45%) of respondents had > 20 years 
in practice, 24% had practiced for 10-20 years and 31% had practiced for less than 10 years. 
The gender distribution was similar (52% male; 48% female).
The most frequent option selected (42%) was offering iNO therapy after shared decision 
with parents. More than a third (36.5%) chose to initiate iNO treatment; a minority (21.5%) 
chose not to consider iNO (figure 2). Based on the results of chi-square tests, there was no 
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influence of practice setting, years in practice, or gender of the treating neonatologist on 
treatment choice.
In the repeated measures ANOVA, ratings of the importance of the factors differed (F (6, 
1644) = 104.58, p < 0.001). Of the seven factors rated, overall among all participants, safety, 
effectiveness (evidence-based care) and provider’s prior experience were rated highest. Cost 
considerations, local hospital practice and medicolegal concerns were rated as least 
important. Table 2 summarizes the odds ratio for ratings for these factors. The rating of the 
seven factors differed based on the management option selected with a significant interaction 
(F (12, 1644) = 9.7, p < 0.001); this interaction was described using multinomial logistics 
regression (Table 2). Evidence on the lack of effectiveness and cost considerations were 
rated highest by physicians who did not consider iNO therapy. Patient-centered-care was 
rated highest by physicians who opted for SDM and provider’s prior experience and safety 
were rated highest by physicians who chose to initiate iNO therapy (figure 2).
Forty-five percent of neonatologists who chose to initiate iNO therapy and 49% who chose 
SDM indicated that the additional information from CPG would influence their decision; 
18% physicians (4% of all surveyed providers) who had chosen not to use this treatment 
noted that additional information on CPG would influence their decision(figure 2). Adding 
information on costs, and an anecdotal instance of a parent being liable for treatment costs 
led to a third (35%) of participants responding that this would influence their decision-
making but was not significantly different between the three initial management strategy 
groups.
Participants provided extensive comments to the free text options, contributing 148 
comments in response to the first follow-up question with CPG recommendations and 192 
comments in response to the cost and potential out-of-pocket costs to parents. The major 
concepts that were communicated along with explanations and select quotes are presented in 
Supplemental tables 1 and 2.
Analysis of comments reveals that most clinicians are aware of the limited evidence and the 
controversy surrounding its use in preterm infants including cost concerns. However, when 
making individual patient care decisions, other factors including absence of alternative 
treatment and the expectation by parents to ‘do something/do everything’ become 
compelling reasons to use iNO; much emphasis was on the clinician’s prior anecdotal 
experience of success in improving oxygenation in a similar infant.
In response to a hypothetical scenario of insurance denial resulting in significant out-of-
pocket expenses for the parent, almost a third of respondents suggested they would treat 
despite the costs; some stating that they do not consider costs when treating patients, or that 
costs should not be considered. 27% of respondents stated that they would discuss the cost 
issue with parents, however how the discussion would impact decision making was not clear. 
13% of respondents suggested that their hospital or health system would absorb costs and 
the patient would not have individual liability.
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Discussion
This study addresses policy implementation and clinical decision making regarding the use 
of a therapy based on pathophysiology for a critically ill premature infant with PH and HRF 
in the face of limited evidence of benefit, potential for harm and high cost using the example 
of iNO. To our knowledge, this is the first study addressing factors influencing provider 
decision-making in neonatal medicine.
Despite recommendations from AAP against the use of iNO, most respondents chose to 
initiate or offer this therapy. The minority who chose not to consider iNO based their 
decision on the lack of supporting evidence and cost concerns; however, 18% in this group 
indicated that the AHA/ATS CPG recommendations basing therapy on pathophysiology 
would influence their decision (figure 2).
Review of comments suggests that most neonatologists who initiate or offer iNO are aware 
of the current trial evidence and cost concerns, however, other factors including safety and 
patient centered care play a dominant role during their decision making leading them to 
choose options that are not effective and expensive. A recent study corroborates our 
findings, reporting that although clinicians understand and appreciate the concept of limiting 
unnecessary testing and treatment, they find it difficult to implement this in practice, partly 
due to their prior experience and the perception of patient expectations 30. In our study, prior 
experience was rated as an important consideration by the group choosing iNO therapy; 
providers believe, in part based on their own experience, that failure to show a benefit in a 
group of patients in the setting of a randomized control trial does not exclude the possibility 
that the treatment will benefit a specific individual infant. A desire to try all options 
irrespective of costs, pressure from parents to do everything possible, community standards 
and expectations and medicolegal concerns represent other reasons clinicians chose to treat 
or offer iNO.
These findings are consistent with those of other studies. It is well known that short-term 
improvement in oxygenation is observed among term and preterm infants with HRF 31 and 
when facing the ‘gravest of circumstances’, neonatologists initiate iNO therapy in an act of 
‘hopeful desperation – it is better to try something than do nothing’. 32 From a physiological 
perspective, after optimization of ventilation and hemodynamics and in the presence of 
echocardiographic evidence of PH, therapy with iNO can potentially improve pulmonary 
blood flow and improve oxygenation. 33
The selective use of iNO for preterm infants with PH physiology and HRF associated with 
PROM with possible pulmonary hypoplasia (physiology-based approach) warrants further 
discussion. Recruitment of preterm infants only with confirmed PH, hypoplasia and HRF in 
trials will prove challenging, but are needed. However, data from subsets of patients in RCTs 
and observational data suggest a benefit. Desandes et al randomized 70 preterm infants with 
HRF and observed improvement in oxygenation only among the subset of 28 infants with 
low pulmonary blood flow by echocardiography (11/35 with iNO and 17/35 controls). 34 
Chock et al evaluated 12 patients with PROM, oligohydramnios and pulmonary hypoplasia 
among the 449 infants enrolled in the Neonatal Research Network PiNO trial. A trend 
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towards improved oxygenation (39±50 mmHg increase vs.a decrease of 11±15) and lower 
mortality (33% vs. 67%), BPD (40% vs.100%) and severe IVH/PVL (1/5 vs.1/2 subjects) is 
suggested in the iNO group compared to controls. 7 In a retrospective audit of infants in 
Australia and New Zealand, functional echocardiography identified preterm infants with PH 
earlier and at a lower OI, but it did not improve survival to discharge. 35 Single-center 
studies also demonstrate survival benefit with iNO among preterm infants with HRF and 
PPROM. 8 Finally, the large, retrospective study from the Pediatrix Database showed a trend 
towards lower mortality among preterm infants with pulmonary hypoplasia and PH (Hazard 
Ratio – 0.67; 95% confidence interval – 0.45-1.01). 6
In contrast, the trials that led to the AAP Committee of Fetus and Newborn report and 
Cochrane report were randomized trials predominantly based on HRF in preterm infants 
without any evidence of long-term benefit. Based on comments written by the survey 
respondents (Supplemental table 1), many practicing neonatal providers are either not 
confident about the results of the randomized trials – or are confused about conflicting 
summaries. The guidelines written by respected physician-scientists and published by 
ATS/AHA and Pediatric Pulmonary Hypertension Network12, 14 and based on 
pathophysiology is appealing to many practicing providers. Personal anecdotal experience of 
improved oxygenation following initiation of iNO led to the use of best clinical judgement 
when caring for each individual infant even if it contradicted NIH/AAP recommendations. 
Lack of alternative therapies and pressure from patients and staff were also cited as reasons 
to initiate iNO. (figure 2) Alternative therapies used for the treatment of PH in preterm 
infants such as sildenafil 36 have a physiological rationale and variable effectiveness based 
on small studies, However, chronic oral sildenafil is the mainstay of long-term PH therapy 
and continues to be used in clinical practice. 37 They are relatively inexpensive compared to 
iNO and as a result have elicited less controversy.
A Cochrane review on this topic 2 concluded that early routine use of iNO in preterm infants 
with HRF does not prevent serious brain injury or improve survival. This review also 
reported a statistically not significant 20% increase in brain injury with iNO (RR 1.2; 95% 
confidence interval .98 – 1.47). In this review, the quality of evidence was judged as 
moderate to high using the GRADE framework 38. More recently, an epidemiological study 
has linked iNO use with a small increase in childhood cancer. 39 Interestingly, the potential 
for harm was not considered in any of the comments. We speculate that neonatologists feel 
that iNO therapy is safe in preterm infants and the increase in brain injury was observed in 
one study 40 but not in other trials. 41, 42
Our study has several strengths including a very specific case-based scenario exploring the 
factors that influenced decisions. This design provided a measurement of the relative 
influence of various factors in clinical decision making by clinicians in diverse practice 
settings. We had a robust response to our invitation for free-text responses with over half of 
respondents providing comments and explanations leading to a richer understanding of the 
decision-making process. This study confirms the opinions of Finer and Evans 17 and Soll 18 
regarding reasons for continued use of iNO among preterm infants by neonatal practitioners.
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This study has several limitations. The case description was brief and did not include 
information regarding ductal and atrial level shunting. Providing this information could have 
enabled respondents to accurately diagnose the presence of PH. The case-based surveys are 
time and effort intensive, and our response rate was low. Our response rate is typical of 
many current surveys, reflecting the decline in response rates of both the general public 
(from 21% in 2006 to 9% in 2016) 43 and physicians who have response rates even lower 
than the general public. 44 This is also true of surveys sent to members of AAP SONPM 
(between 250-300 responses - personal communication with Mr. James Couto, AAP). The 
potential respondent bias associated with the low response raises the possibility that the 
results may not be representative of practicing neonatologists in the US.
Currently there is an increasing focus on considering costs and cost effectiveness 45, 46 in 
medical decision-making. Designing strategies to provide ‘high-value’ care is of tremendous 
interest and much has been written on this topic by professional societies. 47 Current policy 
initiative such as the Choosing Wisely®48 campaign target education and knowledge 
translation strategies to increase appropriate use of medical technologies but do not consider 
factors that may influence physician’s judgement during decision making; these efforts have 
resulted in minimal impact49 or even a contrarian effect50. Successfully designing and 
implementing strategies to increase ‘high-value’ care have proved challenging 51. Although 
a significant proportion of neonatologists indicated that review of CPG would influence their 
decision, many chose to consider iNO treatment in spite of the knowledge of the evidence 
and guidelines and the majority did not change their decision based on the review of CPG 
recommendations. Factors other than knowledge of the evidence and CPG recommendations 
play a decisive role in decision-making. The results of this study suggest that current 
education and knowledge translation strategies while important are not sufficient and an 
improved understanding and targeting of the factors that motivate physician’s decisions is 
essential in designing successful implementation strategies. These may include improved 
efforts to support physicians and parents during difficult decision-making process, especially 
in critical care and increased parent and community engagement.
Conclusions
Most neonatologists chose to offer or initiate iNO treatment based on their previous 
experience and the need to provide patient centered care perceived as a necessity to try all 
options in a critically ill extremely premature infant. The results demonstrate a tension 
between a physiology-based approach backed by anecdotal personal clinical experience and 
an approach based on evidence of effectiveness in clinical trials that needs to be addressed to 
successfully implement high-value care. One approach to resolve this tension is to gather 
more data in preterm infants with PH and HRF. Due to lack of equipoise and difficulties 
with funding and recruitment, placebo controlled trials are unlikely in this population. 
Alternative study designs such as prospective multicenter registries (one such registry is 
being organized by Dr. Kinsella-personal communication), and adaptive designs may be 
helpful in addressing issues regarding the efficacy and safety of therapeutic options in 
extremely preterm infants with life threatening hypoxemia due to PH physiology. The 
second approach would be to develop guideline implementation strategies that include 
efforts beyond traditional clinician education. “Academic detailing” to prospectively collect 
Manja et al. Page 8
J Perinatol. Author manuscript; available in PMC 2019 April 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
prescribing patterns of individual physicians and short- and long-term outcomes of patients 
followed by an interactive discussion of bias and data deficits may be an effective strategy.52 
Further research into the psychology of clinical decision-making is needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Clinical vignette used for the survey. Free text responses were obtained following each 
follow-up question.
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Figure 2. 
Pie chart demonstrating decision regarding initiation of therapy with inhaled nitric oxide and 
the main factors influencing this decision (bullet points). The percentage of respondents 
whose decision was influenced by reviewing current practice guidelines in table 1 are shown 
in boxes outside the pie chart. Some pertinent comments provided by respondents are shown 
in small font.
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Table 1.
Summary of clinical practice guidelines – use of iNO in preterms for pulmonary hypertension or hypoxemic 
respiratory failure
Source (year) Recommendations
NIH consensus (2011)9 • Taken as a whole, the available evidence does not support use of iNO in early-routine, early-
rescue, or later rescue regimens in the care of premature infants of 34 weeks’ gestation who require 
respiratory support.
• There are rare clinical situations, including pulmonary hypertension or hypoplasia, that have been 
inadequately studied in which iNO may have benefit in infants of < 34 weeks’ gestation. In such 
situations, clinicians should communicate with families regarding the current evidence on its risks 
and benefits as well as remaining uncertainties.
AAP 20143 • The results of randomized controlled trials, traditional meta-analyses, and an individualized patient 
data meta-analysis study indicate that neither rescue nor routine use of iNO improves survival in 
preterm infants with respiratory failure (Evidence quality, A; Grade of recommendation, strong).
• The preponderance of evidence does not support treating preterm infants who have respiratory 
failure with iNO for the purpose of preventing/ ameliorating BPD, severe intraventricular 
hemorrhage, or other neonatal morbidities (Evidence quality, A; Grade of recommendation, 
strong).
• The incidence of cerebral palsy, neurodevelopmental impairment, or cognitive impairment in 
preterm infants treated with iNO is similar to that of control infants (Evidence quality, A).
AHA/ATS 201510 • iNO can be beneficial for preterm infants with severe hypoxemia that is due primarily to PPHN 
physiology rather than parenchymal lung disease, particularly if associated with prolonged rupture 
of membranes and oligohydramnios (Class IIa; Level of Evidence B).
Pediatric Pulmonary 
Hypertension Network 
201611
• iNO therapy can be beneficial for preterm infants with severe hypoxemia that is primarily due to 
PPHN physiology rather than parenchymal lung disease, particularly if associated with prolonged 
rupture of membranes and oligohydramnios;
• 2. iNO is preferred over other pulmonary vasodilators in preterm infants based on a strong safety 
signal from short- and long-term follow-up of large numbers of patients from multicenter 
randomized clinical trials for BPD prevention.
Cochrane review 20172 • This review suggests that no clear indications are known for inhaled nitric oxide (iNO) in preterm 
infants.
• Early rescue treatment does not appear successful and may lead to a non-significant increase in 
brain injury. However, preterm infants with clear evidence of pulmonary hypertension have not 
been separately identified in these studies and may constitute a subgroup with a different response.
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Table 2.
The importance of factors influencing clinical decisions to initiate, discuss and offer or not consider iNO 
therapy in extremely preterm infants with pulmonary hypertension and hypoxemic respiratory failure. The 
reference category is – ‘make no mention of iNO therapy to parents’
Factor Option OR (95%CI) Significance
Safety Initiate iNO 1.49 (1.1-2.0) 0.009
Shared decision making with parents 1.38 (1.05-1.83) 0.023
Effectiveness (evidence-based) Initiate iNO 0.39 (0.27-0.58) <0.0001
Shared decision making with parents 0.53 (0.37-0.77) 0.001
Patient centered Initiate iNO 1.39 (1.1-1.75) 0.006
Shared decision making with parents 1.7 (1.35-2.13) <0.0001
Efficient (Cost) Initiate iNO 0.76 (0.59-0.99) 0.038
Shared decision making with parents 0.79 (0.62-1.0) 0.045
Local practice Initiate iNO 1.06 (0.81-1.37) 0.687
Shared decision making with parents 1.06 (0.83-1.36) 0.665
Medicolegal concerns Initiate iNO 1.0 (0.79-1.26) 0.993
Shared decision making with parents 1.15 (0.93-1.44) 0.203
Prior experience Initiate iNO 1.81 (1.32-2.49) <0.0001
Shared decision making with parents 1.05 (0.79-1.39) 0.733
Interpretation of the odds ratio (OR) – The odds of choosing a given option (either to initiate iNO or to offer iNO after shared decision-making) 
over the reference option (not consider iNO) for every unit increase in the independent variable (importance rating on the 7-point Likert scale from 
1=unimportant to 7=critically important). For example, interpretation of the OR for safety in the initiate iNO group - As the rating for safety 
increases by one unit, the odds of choosing the option to initiate iNO increases by 49% (OR 1.49). For OR of <1, the odds decrease – for example 
interpretation of the OR for effective – as the rating for effective increase by 1 unit, the odds of choosing to initiate iNO decrease by 61% (1 - 0.39).
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